Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2051-1426

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? ; volume:6 ; number:1 ; day:3 ; month:12 ; year:2018 ; pages:1-4 ; date:12.2018
Journal for ImmunoTherapy of Cancer ; 6, Heft 1 (3.12.2018), 1-4, 12.2018

Creator: Zhang, Yaxiong
Zhou, Huaqiang
Zhang, Li

Contributor: SpringerLink (Online service)

DOI: 10.1186/s40425-018-0427-6

URN: urn:nbn:de:101:1-2019011922223562527214

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:02 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Zhang, Yaxiong
Zhou, Huaqiang
Zhang, Li
SpringerLink (Online service)

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

Related objects

Reset password